BioSpace News Archive

Cimeio Therapeutics today announced a preclinical research collaboration with Saar Gill, M.D., Ph.D., an associate professor of medicine and a researcher in the Center for Cellular Immunotherapies in the Perelman School of Medicine at the University of Pennsylvania, to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers.

Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in multiple types of cancer at the 2023 European Society for Medical Oncology (#ESMO23) Congress to be held October 20 - 24, 2023.

Supplementing the standard of treatment for early-stage Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of care alone, an ISB-led study shows.

Mirion Technologies, a leading provider of advanced radiation safety solutions, announced its contribution to the Psyche mission, which launched from the agency’s Kennedy Space Center in Florida on October 13, 2023.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer.

Delcath Systems, Inc. (Nasdaq: DCTH) today announced the publication of an article entitled “Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study” in the peer reviewed oncology journal Cancers.

Neuronetics, Inc. announced that clinical findings from the NeuroStar Outcomes Registry are published in the premier journal in the field of neuromodulation, Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation.

Humacyte, Inc. (Nasdaq: HUMA) announced publication of a preclinical study showing the potential for its investigational small-diameter Human Acellular Vessel™ (HAV™) to treat Tetralogy of Fallot, a heart condition that affects one in every 2,000 babies born each year.

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site.

INmune Bio Inc. (NASDAQ: INMB) (the “Company”) today announced that it will host a conference call on Wednesday, November 1, 2023 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023 and to provide a corporate update.